In this episode, we sat down with Clara Burtenshaw, Partner and Investor at Neo Kuma Ventures.
We discussed:
-The evolution of the psychedelics industry from a stigmatized counterculture phenomenon to a scientifically robust industry with support from the FDA for fast-tracking drug development
-The clinical potential of psychedelics to treat illnesses ranging from mental illness to pain management and other nervous system disorders
-Neo Kuma's focus on investing in early stage companies backed by sound science and building a strong founder network
-Predictions that psychedelics as medication is here to stay, and the growing commercialization opportunities in the space
The Pulse by Wharton Digital Health